Ensayos clínicos

8.676 ensayos encontrados

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Randomized, Double-Blind, Efficacy, and Safety Study of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo

INTERVENTIONALInicio: 13 de nov de 2025ID: NCT06804811

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth)

INTERVENTIONALInicio: 30 de jun de 2022ID: NCT05303064

CompletadoFase 1ClinicalTrials.gov

Multiple-dose, Open-label, Randomized, Safety and Pharmacokinetic Study of Tipranavir in Combination With Low-dose Ritonavir in HIV-infected Pediatric Patients

INTERVENTIONALInicio: 1 de nov de 2003ID: NCT00076999

CompletadoFase 3ClinicalTrials.gov

A 26 Week, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase 3 Trial With a 26 Week Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 5 and 10 mg, and Saxagliptin 2.5 and 5 mg in Pediatric Patients With Type 2 Diabetes Mellitus Who Are Between 10 and Below 18 Years of Age

INTERVENTIONALInicio: 11 de oct de 2017ID: NCT03199053

ReclutandoFase 3ClinicalTrials.gov

A Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy, Pharmacokinetics and Safety of Remibrutinib (LOU064) for 24 Weeks in Adolescents From 12 to Less Than 18 Years of Age With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Followed by an Optional Open-label Extension for up to Another 3 Years and an Optional Safety Long-term Treatment-free Follow-up Period for up to an Additional 3 Years

INTERVENTIONALInicio: 11 de jul de 2023ID: NCT05677451

CompletadoFase 3ClinicalTrials.gov

A Stratified, Randomized, Double-blind, Placebo-controlled, Parallel-group, 12 Week Trial Evaluating the Safety and Efficacy of Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50mcg Once Daily Versus Fluticasone Propionate DISKUS 100mcg Once Daily and Placebo in Symptomatic Pediatric Subjects (4-11 Years) With Asthma

INTERVENTIONALInicio: 1 de nov de 2001ID: NCT00920959

Activo, no reclutaFase 3ClinicalTrials.gov

A Phase 3, Randomized, Open-label, Parallel-arm, Active-controlled, Multicenter Study to Evaluate Safety and Efficacy of ALXN1850 Versus Asfotase Alfa Administered Subcutaneously in Pediatric Participants (2 to < 12 Years of Age) With Hypophosphatasia (HPP) Previously Treated With Asfotase Alfa

INTERVENTIONALInicio: 2 de abr de 2024ID: NCT06079372

ReclutandoFase 4ClinicalTrials.gov

A Phase 4, Multicenter, Open-label, Single-arm Study to Investigate the Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate Atopic Dermatitis and High Itch Burden

INTERVENTIONALInicio: 16 de jun de 2025ID: NCT07006792

CompletadoFase 3ClinicalTrials.gov

Immunogenicity Study of the Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months of Age Following a Primary Series of DTaP-IPV-HB-PRP~T Combined Vaccine or of PENTAXIM™ and ENGERIX B® PEDIATRICO at 2, 4, and 6 Months of Age in Healthy Argentinean Infants

INTERVENTIONALInicio: 1 de feb de 2006ID: NCT00303316

DesconocidoClinicalTrials.gov

A Randomized 3-Month, Parallel-Group, Controlled Trial of CALMA M-Health App as an Adjunct to Therapy for the Reduction of Suicidal and Non-Suicidal Self-Injurious Behaviors in Adolescents

INTERVENTIONALInicio: 24 de feb de 2022ID: NCT05453370

CompletadoFase 3ClinicalTrials.gov

Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of Blinatumomab as Consolidation Therapy Versus Conventional Consolidation Chemotherapy in Pediatric Subjects With HR First Relapse B-precursor ALL

INTERVENTIONALInicio: 10 de nov de 2015ID: NCT02393859

Activo, no reclutaClinicalTrials.gov

Protocol-LATAM RegistrAME: Longitudinal Data Collection in Pediatric and Adult Patients With Spinal Muscular Atrophy in Latin America - a Regional Registry

OBSERVATIONALInicio: 17 de ago de 2022ID: NCT05475691

ReclutandoFase 3ClinicalTrials.gov

18-month Double-blind, Randomized, Placebo-controlled, Multicenter, Phase 3 Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease and in Late-infantile and Juvenile-onset Forms of GM1 Gangliosidosis or GM2 Gangliosidosis

INTERVENTIONALInicio: 30 de jun de 2025ID: NCT07082543

ReclutandoClinicalTrials.gov

Incidence of Complications From the Alveolar Opening Maneuver in Mechanically Ventilated Children With Respiratory Distress Syndrome

OBSERVATIONALInicio: 18 de ago de 2025ID: NCT07233304

ReclutandoFase 2ClinicalTrials.gov

A Phase 2, Open-label, Basket Study Investigating the Safety and Efficacy of GTX-102 in Adult and Pediatric Subjects With Deletion- or Nondeletion-type Angelman Syndrome

INTERVENTIONALInicio: 13 de oct de 2025ID: NCT07157254

CompletadoFase 3ClinicalTrials.gov

EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF TOFACITINIB FOR TREATMENT OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA) WITH ACTIVE SYSTEMIC FEATURES IN CHILDREN AND ADOLESCENT SUBJECTS

INTERVENTIONALInicio: 10 de may de 2018ID: NCT03000439

Activo, no reclutaFase 2ClinicalTrials.gov

A Phase 2b, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study of Batoclimab Treatment in Adult Participants With Active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

INTERVENTIONALInicio: 15 de dic de 2022ID: NCT05581199

Activo, no reclutaFase 3ClinicalTrials.gov

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Adult and Adolescent Subjects With Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy

INTERVENTIONALInicio: 19 de dic de 2023ID: NCT06118411

Aún no reclutaFase 3ClinicalTrials.gov

A Study to Evaluate the Dose-exposure, Safety, and Exploratory Efficacy of Nerandomilast in Children and Adolescents From 2 Years to Less Than 18 Years of Age With Fibrosing Interstitial Lung Disease (Part A: Double-blind, Placebo-controlled in Children From 6 to Less Than 18 Years of Age and Open-label Active Treatment in Children From 2 to Less Than 6 Years of Age), Followed by an Open-label Phase With Active Treatment (Part B)

INTERVENTIONALInicio: 6 de jul de 2026ID: NCT07366034

ReclutandoFase 3ClinicalTrials.gov

A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa

INTERVENTIONALInicio: 27 de jun de 2024ID: NCT06468228